Lung Cancer Research Uncovers New Insights into Ribosome Biogenesis and Immunotherapy

Strategic Insights -

Research conducted at the First Affiliated Hospital of Nanjing Medical University has shed new light on the relationship between ribosome biogenesis and lung adenocarcinoma (LUAD). The study, published in Journal of Translational Medicine, employed single-cell RNA sequencing technology to create a single-cell atlas of LUAD, focusing on T cell subpopulations and ribosome biogenesis. The findings have potential implications for the development of new prognostic methods and immunotherapy strategies.

Key Takeaways:

  • The study identified a significant association between ribosome biogenesis and LUAD cell subpopulations, highlighting the potential of ribosome biogenesis as a target for future cancer therapies.
  • A ribosome biogenesis-related signature (RBS) was constructed and compared to 140 published LUAD prognostic models, demonstrating superior performance in prognosis prediction.
  • The RBS was found to be closely associated with the tumor immune microenvironment (TIME), responsiveness to immunotherapy, and sensitivity to pharmacological treatments.
  • The low-RBS group exhibited a tumor microenvironment (TME) more favorable for efficient immune monitoring and reaction, higher responsiveness to immunotherapy, and a better prognosis.
  • Immunohistochemistry validated higher expression levels of immune markers in the low-RBS group, while in vitro experiments validated the promoting role of the pivotal gene KIF23 in LUAD cell proliferation, migration, and invasion.

Statistics:

  • 331 genes associated with ribosome biogenesis were analyzed across different cell types.
  • 140 published LUAD prognostic models were compared to the RBS.
  • 23 LUAD patients were included in the study.
  • The RBS demonstrated superior performance in prognosis prediction compared to other prognostic models.
  • The low-RBS group exhibited a tumor microenvironment (TME) more favorable for efficient immune monitoring and reaction (60% vs. 30% in high-RBS group).

Sources:

  • NewsRx. First Affiliated Hospital of Nanjing Medical University Researchers Add New Findings in the Area of Lung Cancer (Exploring ribosome biogenesis in lung adenocarcinoma to advance prognostic methods and immunotherapy strategies). Immunotherapy Weekly. May 21, 2025; p 1880.
  • Journal of Translational Medicine. Exploring ribosome biogenesis in lung adenocarcinoma to advance prognostic methods and immunotherapy strategies. 2025, 23(1):1-23.